The US Food and Drug Administration is urgently seeking patients that have experienced preterm birth with the market now devoid of treatments and a workshop on developing new therapies upcoming.
A 30 November post on X, formerly known as Twitter, from the FDA Patient Affairs Office seemed ominous: “US...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?